Related Experiment Videos
Plasma-level response relationships with fluoxetine and zimelidine
S A Montgomery1, D Baldwin, A Shah
1Academic Department of Psychiatry, Medical School, St. Mary's Hospital, London, England.
Clinical Neuropharmacology
|January 1, 1990
Summary
Open-dose studies are inadequate for determining optimal antidepressant doses. Fixed-dose studies are recommended, as high concentrations of metabolites like norfluoxetine correlate with poorer outcomes in major depression.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Pharmacy
Background:
- Open-dose rising studies may not effectively establish optimal antidepressant dosages.
- Pharmacokinetic studies of 5-HT uptake inhibitors (zimelidine, fluoxetine) reveal issues with dose determination.
Purpose of the Study:
- To evaluate the adequacy of open-dose rising studies for new antidepressant dose selection.
- To investigate the relationship between plasma concentrations of antidepressants and their metabolites and therapeutic response/side effects.
Main Methods:
- Analysis of pharmacokinetic data from studies on zimelidine and fluoxetine.
- Comparison of findings from small pharmacokinetic studies with large fixed-dose placebo-controlled trials.
Main Results:
- High plasma concentrations of active metabolites (norzimelidine, norfluoxetine) linked to poorer therapeutic response in major depression.
- Elevated drug plasma concentrations associated with increased adverse effects.
- Fixed-dose studies with fluoxetine confirmed lower doses are more effective.
Conclusions:
- Open-dose rising studies are insufficient for establishing optimal antidepressant doses.
- Fixed-dose pharmacokinetic studies are crucial for determining the most effective and safe dosage regimens for new antidepressants.